World's most expensive drug may not be covered by Dutch insurance - ( via NewsPoints Desk)

  • Government advisory group Zorginstituut Nederland recommended that Novartis' spinal muscular atrophy (SMA) drug Zolgensma should not be included in the basic insurance package unless the price is halved, as reported

  • In addition, Novartis should also agree to payment on the basis of the actual results, the institute said.

  • The drug costs €1.9m per treatment, with SMA affecting around 20 children in the Netherlands a year

  • The institute estimates that if the cost were halved, the drug would add around €11 million to the Dutch healthcare budget a year.

To read more NewsPoints articles, click here.